Dexcom CGM users will be able to see CGM data on Fitbit Ionic™ providing a convenient and discreet way to track glucose levels on wrist for users of both Android and iOS devices
SAN FRANCISCO AND SAN DIEGO, CA – September 7, 2017 – Fitbit (NYSE: FIT), the leading global wearables brand, and DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, today announced a collaboration to develop and market products to help people better manage their diabetes and get a more complete picture of their overall health with easy-to-use mobile tools.
The first planned initiative is to bring Dexcom CGM data to Fitbit’s new smartwatch, Fitbit Ionic. Through this experience, Dexcom CGM users on either Android or iOS devices would be able to see both activity and glucose levels, right on their wrist.
“The strength of our brand and our ability to track critical health metrics continuously for up to 4+ days1, coupled with Dexcom’s market leadership in CGM, present a powerful combination that we hope will help millions of people better manage their diabetes,” said James Park, CEO of Fitbit. “With Ionic, we are focused on driving positive health outcomes and more health focused tools, and this collaboration is a wonderful example of how we plan to bring that vision to our users.”
Dexcom CGM Display on Fitbit Ionic will provide data for those living with diabetes
The World Health Organization estimates2 that more than 400 million people around the world are living with diabetes. For those individuals being able to see both physical activity and glucose can be a vital tool for effectively managing their diabetes.
“The collaboration between Dexcom and Fitbit is an important step in providing useful information to people with diabetes that is both convenient and discreet,” said Kevin Sayer, President and CEO, Dexcom. “We believe that providing Dexcom CGM data on Fitbit Ionic, and making that experience available to users of both Android and iOS devices, will have a positive impact on the way people manage their diabetes.”
A health and fitness first platform, Ionic offers a highly personalized experience not previously seen in other smartwatches. Ionic features a relative SpO2 sensor, industry-leading GPS tracking, on-device dynamic workouts, improved heart rate tracking, and water resistance up to 50 meters. Plus, smart features like contactless payments, on-board music, smart notifications, and a variety of popular apps and clock faces available in the Fitbit App Gallery. Ionic also has all the core features from Fitbit like 4+ day battery life, automatic activity and sleep tracking, and cross-platform compatibility.
In addition to the Dexcom CGM display for Fitbit Ionic, with Fitbit’s in-app Community, Dexcom CGM users will now be able to connect with millions of people, where they can ask questions, seek support and share successes in managing their health.
1 Battery life varies with use and other factors.
2 World Health Organization, Diabetes Fact Sheet, updated July 2017, accessed August 31, 2017: http://www.who.int/mediacentre/factsheets/fs312/en/
The companies are targeting availability as soon as possible in 2018 and will continue to explore opportunities to work together to develop tools and resources aimed at helping people better manage their diabetes.
About Fitbit, Inc. (NYSE: FIT)
Fitbit helps people lead healthier, more active lives by empowering them with data, inspiration and guidance to reach their goals. As the leading global wearables brand, Fitbit designs products and experiences that track and provide motivation for everyday health and fitness. Fitbit’s diverse line of innovative and popular products includes Fitbit Surge®, Fitbit Blaze®, Fitbit Charge 2®, Alta HR™, Alta®, Fitbit Flex 2®, Fitbit One® and Fitbit Zip® activity trackers, as well as the Fitbit Ionic™ smartwatch, Fitbit Flyer™ wireless headphones and Fitbit Aria® and Fitbit Aria 2™ Wi-Fi Smart Scales. Fitbit products are carried in 55,000 retail stores across 65 countries around the globe. Powered by one of the world’s largest social fitness networks and databases of health and fitness data, the Fitbit platform delivers personalized experiences, insights and guidance through leading software and interactive tools, including the Fitbit and Fitbit Coach apps, Guided Health Programs, and the Fitbit OS for smartwatches. Fitbit Health Solutions develops health and wellness solutions designed to help increase engagement, improve health outcomes, and drive a positive return for employers, health plans and health systems.
Fitbit and the Fitbit logo are trademarks or registered trademarks of Fitbit, Inc. in the U.S. and other countries. Additional Fitbit trademarks can be found at www.fitbit.com/legal/trademark-list. Third-party trademarks are the property of their respective owners.
Connect with us on Facebook, Instagram or Twitter and share your Fitbit experience.
Fitbit Media Contact
Jen Ralls 415-941-0037 PR@fitbit.com
About DexCom, Inc. (NASDAQ: DXCM)
DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked Dexcom highest in customer satisfaction and loyalty. For more information, visit www.dexcom.com.
DexCom Media Contact Melissa Katz
DexCom Investor Contact Steven Pacelli
This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties including, among other things, statements regarding the future availability of DexCom CGM data on Fitbit Ionic, the development of products that allow people to better manage their diabetes, and the future availability of Fitbit Ionic product features including the Fitbit App Gallery and available apps. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors, including the effects of the highly competitive market in which our respective companies operate, as more fully discussed under the heading “Risk Factors” in each of our most recent reports on Form 10-Q filed with the Securities and Exchange Commission. All forward-looking statements contained herein are based on information available to us as of the date hereof and we do not assume any obligation to update these statements as a result of new information or future events.
First and only single-use, professional CGM system with blinded or unblinded mode
Dexcom, Inc. (NASDAQ:DXCM) announced today the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM)...
Join Dexcom at the upcoming AADE conference from August 9-12, 2019, in Houston, TX. Attendees are invited to attend a special Dexcom product theater and participate in the Dexcom DANA Technology Workshop (details for both...
The ATDC conference will be held on July 11-14, 2019 in Keystone, CO. This event will focus on using new technologies to overcome challenges in day-to-day management of diabetes. Clinical studies and the benefits of Dexcom...